Definition

An off-the-shelf (OTS) preparation of human allogeneic T lymphocytes containing primarily stem cell memory T cells (Tscm) that have been genetically modified to express two chimeric antigen receptors (CARs) targeting the tumor-associated antigens (TAAs) CD19 and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic CD19/CD20-specific CAR-T cells P-CD19CD20-ALLO1 specifically recognize and induce selective toxicity in CD19- and/or CD20-expressing tumor cells. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.